Pharmaceuticals, Biotechnology and Life Sciences
First Known Clinical Report of Retinal Tissue Regeneration Following RPE Transplant Call Scheduled for June 8, 2020 with Therapeutic Area…
WILMINGTON, Mass.–(BUSINESS WIRE)–$CRL–Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will virtually present at the Jefferies Virtual…
Company to host conference call at 8:30 a.m. ET today, June 1 Achieved efficacy and safety endpoints in Phase II…
PARIS–(BUSINESS WIRE)–Vivet Therapeutics announced today that both the Food and Drug Administration (FDA) and the European Commission (EC) have granted…
Streamlining recruitment into studies to speed research BURLINGTON, N.C.–(BUSINESS WIRE)–LabCorp (NYSE: LH), a leading global life sciences company that is…
ZEPOSIA is the first and only approved sphingosine-1-phosphate (S1P) receptor modulator with no genetic test or first dose observation at…
BOCA RATON, Fla.–(BUSINESS WIRE)–TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative women’s healthcare company, announced today the appointment of James C. D’Arecca…
Only PARP Inhibitor to Demonstrate Patient Benefit in a Phase 3 Trial in This Setting KENILWORTH, N.J.–(BUSINESS WIRE)–$MRK #MRK—AstraZeneca and…
TORONTO–(BUSINESS WIRE)– – ATB-346 demonstrates superiority to placebo in reducing osteoarthritis pain – – ATB-346 is more potent than…
Moderna said that the first participants in each age cohort have been dosed in the Company’s Phase 2 study of its mRNA vaccine candidate (mRNA-1273) against the novel coronavirus (SARS-CoV-2).